Telomir Pharmaceuticals, Inc. Common Stock (TELO) is a publicly traded Healthcare sector company. As of July 26, 2026, TELO trades at $1.12 with a market cap of $79.09M and a P/E ratio of 0.00. TELO moved -1.72% today. Year to date, TELO is -13.53%; over the trailing twelve months it is -49.78%. Its 52-week range spans $0.89 to $7.08. Rallies surfaces TELO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Peer-Reviewed Study Shows Telomir-Zn Cuts Zebrafish HOMA-IR from 12 to 3: Telomir Pharmaceuticals published a peer-reviewed preclinical study showing Telomir-Zn normalized fasting blood glucose and reduced HOMA-IR from 10–12 to 3 in a diet-induced zebrafish Type 2 diabetes model after 14 days. Results validate its metal-homeostasis mechanism and underpin its FDA-cleared IND for Phase 1/2 triple-negative breast cancer trials.
| Metric | Value |
|---|---|
| Price | $1.12 |
| Market Cap | $79.09M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.08 |
| 52-Week Low | $0.89 |
| Volume | 80.63K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
TELO analyst coverage data. Average price target: $0.00.